EP0596912A4 - Modulation and diagnosis of cytokine dysfunctions. - Google Patents

Modulation and diagnosis of cytokine dysfunctions.

Info

Publication number
EP0596912A4
EP0596912A4 EP19920914799 EP92914799A EP0596912A4 EP 0596912 A4 EP0596912 A4 EP 0596912A4 EP 19920914799 EP19920914799 EP 19920914799 EP 92914799 A EP92914799 A EP 92914799A EP 0596912 A4 EP0596912 A4 EP 0596912A4
Authority
EP
European Patent Office
Prior art keywords
dysfunctions
cytokine
diagnosis
modulation
cytokine dysfunctions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19920914799
Other versions
EP0596912A1 (en
Inventor
William Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEM Pharmaceuticals Corp
Original Assignee
HEM Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HEM Pharmaceuticals Corp filed Critical HEM Pharmaceuticals Corp
Publication of EP0596912A1 publication Critical patent/EP0596912A1/en
Publication of EP0596912A4 publication Critical patent/EP0596912A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
EP19920914799 1991-07-16 1992-06-23 Modulation and diagnosis of cytokine dysfunctions. Withdrawn EP0596912A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73022991A 1991-07-16 1991-07-16
US730229 1991-07-16
PCT/US1992/005286 WO1993001717A1 (en) 1991-07-16 1992-06-23 Modulation and diagnosis of cytokine dysfunctions

Publications (2)

Publication Number Publication Date
EP0596912A1 EP0596912A1 (en) 1994-05-18
EP0596912A4 true EP0596912A4 (en) 1994-07-27

Family

ID=24934492

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920914799 Withdrawn EP0596912A4 (en) 1991-07-16 1992-06-23 Modulation and diagnosis of cytokine dysfunctions.

Country Status (11)

Country Link
EP (1) EP0596912A4 (en)
JP (1) JPH07501787A (en)
CN (1) CN1068738A (en)
AU (1) AU2268892A (en)
CA (1) CA2113573A1 (en)
IE (1) IE922145A1 (en)
MX (1) MX9204164A (en)
PT (1) PT100688A (en)
TW (1) TW271398B (en)
WO (1) WO1993001717A1 (en)
ZA (1) ZA925263B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0286224A2 (en) * 1987-03-23 1988-10-12 Hem Pharmaceuticals Corp. Treatment of human viral infection by dsRNA combined with viral inhibitors
EP0299745A2 (en) * 1987-07-17 1989-01-18 Hem Pharmaceuticals Corp. Double-stranded RNA correction of RNase L deficiency
EP0300680A2 (en) * 1987-07-17 1989-01-25 Hem Pharmaceuticals Corp. Doublestranded RNA correction of abnormalities in circulating immune complexes and monocyte function
EP0347501A1 (en) * 1988-06-20 1989-12-27 Hem Pharmaceuticals Corp. Modulation of lymphokine-resistant cellular states by dsRNAs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0286224A2 (en) * 1987-03-23 1988-10-12 Hem Pharmaceuticals Corp. Treatment of human viral infection by dsRNA combined with viral inhibitors
EP0299745A2 (en) * 1987-07-17 1989-01-18 Hem Pharmaceuticals Corp. Double-stranded RNA correction of RNase L deficiency
EP0300680A2 (en) * 1987-07-17 1989-01-25 Hem Pharmaceuticals Corp. Doublestranded RNA correction of abnormalities in circulating immune complexes and monocyte function
EP0347501A1 (en) * 1988-06-20 1989-12-27 Hem Pharmaceuticals Corp. Modulation of lymphokine-resistant cellular states by dsRNAs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9301717A1 *

Also Published As

Publication number Publication date
PT100688A (en) 1993-10-29
WO1993001717A1 (en) 1993-02-04
CA2113573A1 (en) 1993-02-04
ZA925263B (en) 1993-03-31
TW271398B (en) 1996-03-01
EP0596912A1 (en) 1994-05-18
AU2268892A (en) 1993-02-23
CN1068738A (en) 1993-02-10
JPH07501787A (en) 1995-02-23
IE922145A1 (en) 1993-01-27
MX9204164A (en) 1993-05-01

Similar Documents

Publication Publication Date Title
EP0269302A3 (en) Imaging apparatuses and methods
EP0477969A3 (en) Fixater and recording apparatus using the same
EP0313943A3 (en) 1,2-naphtalocyanine near-infrared absorbent and recording/display materials using same
OA09736A (en) "Human interleukin-3 and muteins thereof".
NZ229958A (en) Bismuth ranitidine salts, and their solvates
EP0194541A3 (en) Heteropolyacide h8pmo10vo39, its anhydride pmo10vo35 and its use
EP0344110A3 (en) Substituted naphthacenes-5,12-diones and their use
ZA926189B (en) Beta-Phenylisoserine derivatives and their preparation and use.
EP0601405A3 (en) Polymeric borosilazanes and alumosilazanes and their use.
EP0255801A3 (en) Anilinotriazines and their use
EP0432670A3 (en) Converter and discharge-lamp operating apparatus using the converter
EP0640093A4 (en) Human crabp-i and crabp-ii.
EP0465132A3 (en) Dna and its use
IL92281A0 (en) Polyimidesiloxanes,their preparation and use
EP0596912A4 (en) Modulation and diagnosis of cytokine dysfunctions.
EP0344109A3 (en) Substituted naphthacene-5,12-diones and their use
ZA9110045B (en) Pyrimidinyl-and triazinyl-salicylamides and their use and preparation
EP0600294A3 (en) Polyether substituted imide compounds and their use.
EP0432353A3 (en) Resistor paste and its use
IL116226A0 (en) Substituted n-phenyl and n-heteroarylalkylcarbamates their preparation and use
GB9002217D0 (en) Back rehabilitation procedure and means
EP0310432A3 (en) Data converter and image reader using the same
ZA933815B (en) Pyrimidinyl- and triazinyl-salicyl- and -picolyl- amides and the use and preparation thereof.
GB9120768D0 (en) Diagnostic and prognastic materials and methods
EP0438711A3 (en) Polysilazanes, their preparation and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19940609

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: A61K 31/70

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960102